<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745247</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0888</org_study_id>
    <secondary_id>2020-A03467-32</secondary_id>
    <nct_id>NCT04745247</nct_id>
  </id_info>
  <brief_title>Stimulate the Face to Improve Tactile Acuity on the Hand</brief_title>
  <acronym>FACEHAND</acronym>
  <official_title>Using a New Form of Cross-border Plasticity Within the Somatosensory Cortex: Stimulate the Face to Improve Tactile Acuity on the Hand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a comparative study, to show that the administration of RSS stimulation on the&#xD;
      face compared to the administration of strategy Sham stimulation, results in an temporary&#xD;
      improvement in the tactile acuity of the hand in patients with tactile acuity impairment of&#xD;
      the hand due to stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Tactile acuity : 2 point discrimination test</measure>
    <time_frame>Week 3</time_frame>
    <description>The Primary outcome measure is a composite of 2point discrimination test (2PDT) and Absolute threshold detection test after 3h of RSS.&#xD;
Spatial discrimination of the finger, Absolute threshold detection of the finger.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tactile acuity : Absolute threshold detection test after 3h of RSS</measure>
    <time_frame>Week 3</time_frame>
    <description>The Primary outcome measure is a composite of 2point discrimination test (2PDT) and Absolute threshold detection test after 3h of RSS.&#xD;
Spatial discrimination of the finger, Absolute threshold detection of the finger.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Jebsen-Taylor hand function test (JTHFT)</measure>
    <time_frame>Week 3</time_frame>
    <description>Overall functionality of the hand, especially with regard to handling objects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire comfort/ease to use</measure>
    <time_frame>Week 3</time_frame>
    <description>A self-reported assessment will be administered after the completion of testing procedure: a custom-made questionnaire including the ease of use, perceived sensations during RSS, easy positioning, pain on removal, positive and negative aspects of RSS, willing to continue using after release from the hospital, and willing to recommend to others.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Stroke</condition>
  <condition>RSS</condition>
  <condition>Face</condition>
  <arm_group>
    <arm_group_label>RSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repetitive somatosensory stimulation (RSS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham RSS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham Repetitive somatosensory stimulation (RSS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RSS</intervention_name>
    <description>Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours&#xD;
Sham Repetitive somatosensory stimulation (RSS) applied on a small region of the face for 3 hours : the number of stimuli is reduced compared to the effective RSS</description>
    <arm_group_label>RSS</arm_group_label>
    <arm_group_label>Sham RSS</arm_group_label>
    <other_name>Repetitive somatosensory stimulation (RSS)</other_name>
    <other_name>Sham Repetitive somatosensory stimulation (RSS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 30-80 years old&#xD;
&#xD;
          -  Patients with diagnosis of unilateral (both right and left) ischemic or haemorrhagic&#xD;
             stroke&#xD;
&#xD;
          -  Stroke event dates at least 3 months before the date of inclusion to the study&#xD;
&#xD;
          -  Mild-to-moderate sensory loss at the fingers of the hand contralateral to the stroke&#xD;
             lesion (affected hand)&#xD;
&#xD;
          -  Capacity to provide written consent&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
          -  Sensory impairment attributable to diabetes history, peripheral vascular disease or&#xD;
             neuropathy&#xD;
&#xD;
          -  Severe speech disorder, global aphasia and/or cognitive impairment&#xD;
&#xD;
          -  Multiple stroke events&#xD;
&#xD;
          -  Bilateral stroke event&#xD;
&#xD;
          -  Hemineglect&#xD;
&#xD;
          -  History of neurological or psychiatric illness&#xD;
&#xD;
          -  Allergy to glue/tape&#xD;
&#xD;
          -  Male participants refusing to shave their moustaches or beards during the study&#xD;
&#xD;
          -  Other experimental procedure is forbidden during the weeks where the study is&#xD;
             performed&#xD;
&#xD;
          -  Pregnant, parturient and lactating women&#xD;
&#xD;
          -  Persons deprived of their liberty&#xD;
&#xD;
          -  Adult persons subject to a legal protection measure: guardianship, curatorship&#xD;
&#xD;
          -  Congenital or acquired malformation/injury of the test finger&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impossibility to maintain hand position necessary for the tests due to severe&#xD;
             spasticity&#xD;
&#xD;
          -  Severe impairment of the sensibility of the face preventing the administration of the&#xD;
             RSS&#xD;
&#xD;
          -  Severe impairment of the absolute touch detection at the affected hand preventing&#xD;
             measurement (threshold 512 mN)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques LUAUTE, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Médecine Physique et Réadaptation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques LUAUTE, PU-PH</last_name>
    <phone>4 78 86 50 23</phone>
    <phone_ext>+33</phone_ext>
    <email>jacques.luaute@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles RODE, PU-PH</last_name>
    <phone>4 78 86 50 66</phone>
    <phone_ext>+33</phone_ext>
    <email>gilles.rode@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupement Hospitalier du Sud - Hôpital Henry Gabrielle</name>
      <address>
        <city>Saint-Genis-Laval</city>
        <zip>69230</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques LUAUTE, PU-PH</last_name>
      <phone>4 78 86 50 23</phone>
      <phone_ext>+33</phone_ext>
      <email>jacques.luaute@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques LUAUTE, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles RODE, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure HUCHON, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

